Abstract Library

#4420 Nab-paclitaxel plus bevacizumab for patients with previously treated, metastatic extrapulmonary neuroendocrine carcinomas (EP-NECs): A multicentre, open-label, phase II trial

Introduction: No standard therapies beyond first line are established for advanced EP-NECs. Paclitaxel is also active in NECs however there is no data on the role of nab-paclitaxel.

Conference:

Presenting Author: Zhang P

Authors: Zhang P, Li S, Li J, Shen L, Lu M,

Keywords: extrapulmonary neuroendocrine carcinoma, nab-paclitaxel, bevacizumab,

#4407 Characterisation of patients with neuroendocrine tumours in a specialised care institution in oncological endocrinology Bogotá, Colombia

Introduction: Neuroendocrine tumours (NETs) are heterogeneous malignancies that arise from the diffuse neuroendocrine system. Its incidence has increased in the last 3 decades. They have a relatively indolent growth rate and are capable of secreting peptide hormones and biogenic amines.

Conference:

Presenting Author: Florez A

Authors: Rueda M, Florez A, Luna F, Fuentes O, Lizarazo D,

Keywords: Neuroendocrine tumour,

#4345 Real-life results of the treatment with lutetium in advanced neuroendocrine tumours

Introduction: Therapy using lutetium-177 dotatate (177LU) was approved in Europe in 2017 for the treatment of advanced neuroendocrine tumours (NETs). Since then, it has become part of the strategies for treating NETs, making it now possible to evaluate real-life results.

Conference:

Presenting Author: Campos Ramírez S

Authors: Campos Ramírez S, Andrés A, Gómez Mugarza P, Blanco Abad C, Monreal Cepero M,

Keywords: Neuroendocrine tumour, Lutetium, Efficacy, Toxicity, Real-Word Evidence,

#4229 Bone health in neuroendocrine neoplasms

Introduction: Neuroendocrine neoplasms (NENs) are a heterogeneous group of rare neoplasms, classified according to localization of the primary tumor, differentiation and grading. The effect of localized or advanced NENs and systemic therapies on bone and muscle health is still controversial.

Conference:

Presenting Author:

Authors: Casabella A, Veresani A, Boschetti M, Sulli A, Hasballa I,

Keywords: Bone health, neuroendocrine neoplasm, TBS, RSMI, T-Score,

#3645 Nab-paclitaxel plus bevacizumab for patients with previously treated, metastatic neuroendocrine carcinomas (NEC) – A multicenter, open-label, phase II trial

Introduction: No standard therapies beyond first line are established for advanced NECs. Most NECs are hyper vascular, and the efficacy of paclitaxel-based combination regimens in the treatment of multiple digestive cancers has been reported.

Conference:

Presenting Author:

Authors: Zhang P, Li S, Li J, Lin S, Ming L,

Keywords: NEC, nab-paclitaxel, bevacizumab,